Biomarkers (short for biological markers) are substances which can be objectively measured and evaluated as an indicator of risk or progression of a disease. White matter loss is a common finding in Alzheimer’s disease (AD), but the mechanisms are not well understood. We investigate white matter measures to see whether they may be useful as a non-invasive biomarker in the early diagnosis of Alzheimer’s Disease.
To investigate whether microstructural white matter changes similar to those identified in AD patients can be detected in cognitively normal non-demented individuals destined to develop amnestic mild cognitive impairment (aMCI).
To examine the relationships between brain amyloid burden as measured by cerebrospinal fluid (CSF) Aβ42 levels and white matter degeneration at different stages of the AD process.